New Arcturus Data Supports Liver mRNA Platform as Company Advances Faster Path for Improved OTC
Arcturus shares positive OTC deficiency Phase 2 findings, plans to add ARCT-2601 by year-end 2026, and acquires AI firm myNEO.
/ 491 items
#XY Event-Driven Stocks↓
Rapport Therapeutics Shares Fall After CEO Comments on RAP-219 Bipolar Mania Trial
Shares of Rapport Therapeutics dropped after conference remarks on RAP-219’s bipolar mania study, weeks before the planned October readout.
ORKA Drops After Encouraging Week 28 Data as Investors Take Profits
Analysts called the readout in line with base case. Next tests: 52-week EVERLAST-A in December and EVERLAST-B data in Q4.
Immunovant Ends Cutaneous Lupus Study After IMVT-1402 Fails to Beat Placebo
Immunovant ends IMVT-1402 in cutaneous lupus after a 57-patient study missed its CLASI-A primary endpoint. Other programs remain on track.
Roche and Ionis Report Phase 3 Proteinuria Win for Sefaxersen in IgA Nephropathy
Roche-Ionis sefaxersen beat placebo on proteinuria at week 37 in IgAN Phase 3. Monthly shot enters crowded market vs Novartis Fabhalta.
FDA Clears TriSalus’ TriNav Advance for Hard-to-Reach Liver Tumors
FDA clears TriSalus’ TriNav Advance, designed to push more treatment into liver tumors and less into healthy tissue via a SmartValve.